A number of studies have suggested that prior chemotherapy correlates negatively with the efficiency of hematopoietic stem cell mobilization. However, little data exist with regard to the relative effects of the specific chemotherapeutic drug classes. We retrospectively reviewed the records of 201 consecutive patients with nonmyeloid malignancies undergoing CD34 þ cell mobilization with chemotherapy þ granulocyte colony-stimulating factor (G-CSF). The number of prior chemotherapy courses correlated negatively with the peripheral CD34 þ cell concentration (pCD34) on the first day of collection (Po0.001). No significant correlation was found for age, gender, tumor primary, mobilization chemotherapy regimen, disease status, marrow involvement, prior radiation therapy, or dose and timing of G-CSF administration. When the number of courses of individual classes of chemotherapeutic agents was correlated with pCD34, only exposures to platinum compounds (P ¼ 0.001) and alkylating agents (P ¼ 0.01) were found to be independent negative predictive factors for pCD34. Within classes, DNA crosslinking agents and etoposide appeared possibly more damaging than DNA methylating agents and doxorubicin, respectively. None of the drug classes showed evidence of recovery. We conclude that exposure to chemotherapy, especially platinum compounds and alkylating agents, should be minimized prior to mobilization.
motherapy; CD34
High-dose therapy with peripheral blood stem cell (PBSC) support has been successfully used in the management of a number of malignancies. PBSCs are usually mobilized from the marrow by the action of hematopoietic growth factors (with or without chemotherapy), harvested by a cell separator, and quantified by CD34 þ cell enumeration.
The identification of factors that correlate with a patient's ability to obtain high concentrations of circulating CD34 þ cells during the mobilization process has been the objective of a number of prior studies. These have disagreed over the influence of age, [1] [2] [3] [4] gender, [4] [5] [6] interval from last chemotherapy, 1, 3, 4, 7, 8 bone marrow involvement, 1, 3, 4, 8, 9 tumor primary, 5,9,10 disease status, [3] [4] [5] and prior radiation, 3, 4, 9, 11, 12 suggesting that these are, at best, weak predictive factors. Overall, however, one of the most consistent negative influences on mobilization efficiency has been the amount of prior chemotherapy. Although the number of courses of prior chemotherapy usually correlates negatively with mobilization efficiency, rather minimal and conflicting data exist with regard to the relative effects of the specific chemotherapeutic drug classes. For example, while some studies have suggested that alkylating agents may be more damaging, 12, 13 other analyses have yielded no differences. 3 In this study, we have retrospectively analyzed the effect of prior chemotherapy with the various drug classes on the peripheral blood CD34 þ cell concentration (pCD34) at the initiation of harvest. In order to minimize the effect of the mobilization regimen, we restricted the analysis to patients receiving chemotherapy and granulocyte colony-stimulating factor (G-CSF).
Methods

Patients
Data from 201 consecutive adult patients with nonmyeloid malignancies and available peripheral CD34 þ cell concentrations on the day of first collection were included. All patients had undergone mobilization with chemotherapy and recombinant G-CSF at LDS Hospital or the University of Utah. Most patients had received G-CSF 10 (n ¼ 161) or 6 (n ¼ 33) mg/kg/day subcutaneously beginning on day 5 (n ¼ 100) or 6 (n ¼ 79) following the initiation of chemotherapy. Complete blood counts were followed daily and, when the WBC had risen to greater than 800 cells/ml, daily pCD34 was determined. PBSC collections were begun at the discretion of the attending physician, usually following a recovery of the peripheral white blood count (pWBC) to 45.0 Â 10 9 cells/l (median: 10 Â 10 9 cells/l) and a pCD34 410 Â 10 6 cells/l (median: 60 Â 10 6 cells/l). 
Prior chemotherapeutic agents
Results
The characteristics of the 201 patients are summarized in Table 1 . The patients had received a mean of 6.173.3 premobilization chemotherapy courses utilizing various agents. In all, 40 patients were mobilized following standard-dose salvage chemotherapy used in the treatment of their specific primary tumors, while the remainder received various intermediate-dose chemotherapy regimens designed for mobilization. The patients were relatively uniform in the dosage and timing of G-CSF. The specific chemotherapeutic agents received by the 201 patients prior to mobilization are summarized in Table 2 . Cyclophosphamide and doxorubicin had been used most often. Some agents such as fludarabine and venorelbine were received too infrequently for a significant evaluation of their effects on pCD34.
The correlation of several possible predictive factors for pCD34 in our patient population is shown in Table 3 . The mobilization chemotherapy regimen, G-CSF dose, and G-CSF schedule did not correlate with pCD34. A statistical trend was noted for prior radiation. However, only the number of prior chemotherapy courses was significant (P ¼ 0.001). Regression modeling suggested that each course of chemotherapy resulted in a decrease of 9.4 cells/ml for the pCD34 on the first day of harvest.
The relation between pCD34 and number of prior courses of drugs from the various chemotherapeutic agent classes is shown in Table 4 . On univariate analysis, prior exposure to platinum compounds and alkylating agents had the strongest negative effect on pCD34. Only the number of platinum courses was more predictive than the total number of chemotherapy courses. Within drug classes, DNA crosslinking agents appeared more damaging than methylating agents and DNA-intercalating agents (doxorubicin) than nonintercalating topoisomerase inhibitors (etoposide). On a multivariate analysis, which included the total number of chemotherapy courses, only the number of prior courses of platinum compounds (P ¼ 0.001) and alkylating agents (P ¼ 0.01) were found to be independent negative predictive factors for pCD34. Regression analysis suggested that each course of platinum decreased the pCD34 on the first day of collection by 18 cells/ml, and each alkylating agent course by 6.6 cells/ml.
The potential for recovery from the effects of the different drug classes was investigated by correlating the time from the last drug administration with the pCD34 on the first day of harvest (Table 5 ). Although some of the patients had relatively long intervals, we could find evidence of recovery for none of the drug classes.
Discussion
In this study, we have examined a number of factors potentially related to the ability to obtain higher levels of pCD34 at the initiation of harvest. Of several possible end points for mobilization efficiency, we chose pCD34 on the first day of harvest as the most direct measurement. For practical reasons, many other studies have utilized the harvest yield. We and others have shown a high correlation between these two end points. 15 However, we have also suggested previously that the end point of harvest yield does add additional confounding variables not related to mobilization such as cell separator collection efficiency. 16 We also attempted to design our study in a manner that would minimize the effect of mobilization regimen variables as confounding factors. As randomized trials have demonstrated the superiority of chemotherapy þ growth factors over growth factors alone, 17 we included only patients receiving both chemotherapy and G-CSF. Randomized trials have also suggested that the dose of G-CSF correlates with the mobilization efficiency when G-CSF is used alone 18 or following chemotherapy, 19 although the latter finding has not been consistent. 20 In our patient population, the G-CSF dose did not correlate with pCD34. There are several possible reasons why such an effect, if it exists, may have been more difficult to detect. The first is that our patient population is relatively homogeneous in terms of the G-CSF dose received. Thus, 80% of our patients received a dose of 10 mg/kg/day and all but seven patients received doses of 6 or 10 mg/kg/day. A second reason may be that the range of doses of G-CSF received by our patients is not sufficient to show a dose effect in a study of our sample size. If so, our results would be consistent with those of Andre et al, 20 who found no significant difference in CD34 þ cell harvest yields between 131 patients randomized to receive 5 or 10 mg/kg/day of G-CSF following mobilization chemotherapy. That doses greater than 10 mg/kg/day may be superior to lesser doses, or that wider disparity in the doses administered compared to the 5 mg/kg/day difference in the study arms in the trial of Andre et al, are needed to show an effect was suggested by the small study of Demirer et al, 19 which found superior collections following 16 as compared to 8 mg/kg/day following mobilization chemotherapy.
It has also been suggested that patient case mix may affect the sensitivity of detecting significant differences among groups receiving varying doses of G-CSF. Thus, using G-CSF alone, Weaver et al 18 noted that the differential effect of an increased dose (30 vs 10 mg/kg/ day) on CD34 þ cell collections seemed to be greater in patients who had received lesser doses of premobilization chemotherapy. However, this result was not seen in the study of Andre et al. These findings may suggest that differences between harvest results from good and poor risk patients are minimized with chemotherapy þ G-CSF mobilization regimens and/or use of G-CSF doses o10 mg/kg/day such as were received by our patient population and that of Andre et al.
In agreement with previous studies, 3,4,6-8 the amount of prior chemotherapy is a significant predictor for mobilization efficiency in our study. Prior radiation therapy appears to have less effect, a result that conflicts with some 3,4,9 but not other 11, 12 studies. However, our ability to detect an influence was likely related to the use of radiation in only 24% of our patients, and only one course of radiation was received by 88% of these. While such limited radiation appears to have little impact, our results do not rule out a negative effect from more extensive treatments.
More data are needed with regard to the effects of individual classes of drugs received prior to stem cell mobilization. Drake et al 21 proposed a scoring system based largely on murine studies that evaluated the repopulating ability of bone marrow cells that had been exposed to various chemotherapeutic agents. In general, Drake's system classified DNA alkylating agents as most, Table 2 Numbers of patients exposed to individual chemotherapeutic classes and agents 22 found a correlation between the scoring system and CD34 þ cell collections. Some problems of the Drake's system, for current use, include a lack of initial grounding in human patient data, exclusion of antimetabolites (especially when 5-FU, a commonly used drug, had shown adverse effects in the murine studies that formed the basis of their system), and a lack of inclusion of newer and frequently used agents such as the taxanes.
In order to address some of these issues, we performed a retrospective study correlating the exposure to seven chemotherapeutic drug classes in common use with mobilization efficiency. Our results revealed some similarities and some differences with those of Drake et al. In our patients, prior exposure to DNA crosslinking agents and platinum analogs appeared to carry the greatest risk of impairment, while antimetabolites seemed to have little, if any, effect. In addition, we could find no evidence of recovery over time for any of the drug classes. This result is consistent with some 3, 4 but not other 1, 7, 8 prior work that has examined the relation between time since last chemotherapy and mobilization efficiency.
The mechanism(s) by which prior chemotherapy decreases the concentration of mobilized peripheral blood CD34 þ cells is not entirely clear. Studies in rodents have suggested that alkylating agents and platinum analogs can produce a sustained reduction in the number of effective marrow stem cells as evidenced by decreased repopulating ability. 23 While this may result, at least in part, from a direct effect on stem cells, cyclophosphamide has also been shown to negatively affect the ability of the marrow stroma to support hematopoietic progenitors. 24, 25 We conclude that prior chemotherapy is the most important potentially controllable variable for stem cell mobilization. Minimization of exposure to chemotheraputic agents, especially platinum analogs and DNA crosslinking agents, should increase CD34 þ cell harvest yields. 
